The 3rd Anniversary of the Science and Technology Innovation Board has outstanding performance in biomedicine!

[Pharmaceutical Network Pharmaceutical Stock Market] On July 25, Qiming Venture Capital, an innovative drug research and development enterprise, Yifang Bio, successfully landed on the Science and Technology Innovation Boa.
The number of shares in the company's public offering this time is 115 million shares, and the total share capital after the issuance is 575 million shar.
The number of publicly issued shares accounts for 20% of the total share capital after the public offeri.
The company plans to invest 409 billion yuan in the fundraising project, which will help the company accelerate the clinical development of its existing product pipeli.
It is understood that on July 22, the Science and Technology Innovation Board ushered in the third anniversary of the opening of the mark.
In the past three years, the number of companies listed on the Science and Technology Innovation Board has grown to 439, with a total market value exceeding 5 trillion yuan, and IPO financing exceeding 600 billion yu.
According to statistics, as of July 22, a total of 96 companies listed on the Science and Technology Innovation Board belong to the biological indust.
According to the industry, the Science and Technology Innovation Board has become the main global listing place for biopharmaceutical companies outside the United States and Hong Kong, Chi.
As the main position of China's "hard technology" enterprises, the STAR Market companies have a remarkable "high R&D" characteristic, and are higher than the overall level of the A-share market in indicators such as R&D expenditure growth rate, R&D personnel ratio, and R&D investme.
Statistics show that in 2021, the R&D investment of the companies on the Science and Technology Innovation Board will increase by 29% year-on-year, reaching 8240 billion yuan, and the ratio of R&D investment to operating income will average 1
The analysis by the Wisdom Bud Innovation Research Center shows that the R&D investment intensity (referring to the ratio of enterprise R&D investment to total revenue) of listed companies on the Bio-industry Science and Technology Innovation Board is 2 times higher than the overall level of the Science and Technology Innovation Boa.
Among them, the overall R&D investment intensity of biomedical science and technology innovation board enterprises is as high as 3Looking further into the sub-sectors in the bio-industry, the 96 bio-industry STAR Market listed companies are mainly concentrated in the bio-pharmaceutical industry and the bio-medical engineering industry, with 48 and 42 companies respective.
Among them, the overall R&D investment intensity of 48 biopharmaceutical companies reached 38%, which is much higher than the overall R&D investment intensity of the Science and Technology Innovation Boa.
It can be seen that companies listed on the Science and Technology Innovation Board of the biopharmaceutical industry show the characteristics of high R&D investme.
So what kind of company is Yifang Bio, which successfully landed on the Science and Technology Innovation Board on July 25? According to the data, Yifang Bio is an innovative drug research and development enterprise with a global perspective based in China, focusing on major diseases such as tumors and metabolic diseas.
Disease are.
Based on its outstanding and rich drug development strength and experience, Yifang Bio has independently developed a series of innovative targeted drugs, covering solid tumors such as non-small cell lung cancer, breast cancer, and colorectal cancer, as well as metabolic diseases such as hyperuricemia and go.
disea.
The product pipeline currently has 3 core products in clinical trials and 5 pre-clinical research projects, all of which have been approved for Phase II or Phase III clinical tria.
Yifang Bio said that listing on the Science and Technology Innovation Board is a new opportunity for the compa.
The company will accelerate the process of product industrialization and marketization; at the same time, it will promote more preclinical candidate compounds to enter global clinical trials and continue to enrich the company's product pipeli.
The establishment of the Science and Technology Innovation Board provides more options for Chinese biopharmaceutical companies and activates the innovation vitality of the entire industry cha.
The industry pointed out that in three years, many innovative drugs have matured in the "experimental fiel.
For example, Zejing Pharmaceutical independently developed and marketed innovative small-molecule targeted drugs for the first-line treatment of liver cancer; Toripalimab independently developed by Junshi Bio received FDA breakthrough therapy designation,e.
Today, the biomedical field of the Science and Technology Innovation Board has initially formed the agglomeration effect and demonstration effect of drug research and development enterpris.
As of July 20, the total market value of 35 companies exceeded 10 billion yuan; the total market value of BeiGene, Bloomage Bio, and Junshi Bio exceeded 50 billion yuan; the market value of BeiGene was about 144 billion yu.
Analysts said that with the implementation of the IPO fundraising project, Yifang Bio will strengthen the company's new drug research and development capabilities, improve the development capabilities of preclinical and clinical products, and accelerate the process of listing the company's main self-developed products at home and abroad, so as to continuously improve its own In terms of market position and international competitiveness in the innovative drug industry at home and abroad, the company will fully enter the "fast lane" of developme.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.